Indication

IDH1 R132G

1 clinical trial

1 product

Clinical trial

Phase 2 Study of Olutasidenib With Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations

Status: Not yet recruiting, Estimated PCD: 2029-06-01

Product